Expanded enrollment into Phase II trial of MVI-816

Madison Vaccines has announced expanded enrollment of patients in the Phase II trial of its lead product candidate: MVI-816 (also known as pTVG-HP). MVI-816 is an immunotherapeutic agent that is being tested in locally progressive forms of prostate cancer after first-line therapy. … READ MORE …

NICE, abiraterone, and the economics of treatment

On Friday last week the National Institute for Health Care Excellence (NICE) in England came to the conclusion that abiraterone acetate (Zytiga) is not cost-effective in the treatment of men with chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC), based on the most recently proposed price to the National Health Service. … READ MORE …

A brief cornucopia of interesting articles on important topics

Usually we provide summaries of specific articles for our readers, but in the past couple of weeks there have been a number of interesting, relatively short articles on the management of prostate cancer that are well worth reading in their entirety, … READ MORE …

Bill Manning’s blog: Part V

Here is the fifth of Bill’s blog posts. He, and we, hope it will be helpful to all those battling late stage prostate cancer as he takes advantage of some of the new drugs that have come to market over the past couple of years. Click here for earlier parts if you missed them. … READ MORE …

Future access to treatment with sipuleucel-T: a serious issue

A significant and recent decline in the value of shares in Dendreon is raising major questions about the long-term viability of the company, and therefore whether it will continue to be possible for patients to gain access to treatment with the immunotherapeutic agent sipuleucel-T (Provenge). … READ MORE …

Enzalutamide and quality of life in post-chemotherapy mCRPC patients

A newly published paper in The Lancet Oncology has provided data on several of the prospectively defined secondary endpoints from the AFFIRM trial of enzalutamide vs. a placebo in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) after progression on treatment with docetaxel + prednisone. … READ MORE …

Early identification of androgen receptor gene amplification and prostate cancer risk

Historically, it has generally been assumed that androgen receptor gene amplification was a result of androgen deprivation therapy (ADT) and occurred in some 20 to 30 percent of men with castration-resistant prostate cancer (CRPC). However, … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,133 other followers